Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - Northfield Laboratories, Inc. (NASDAQ: NFLD) reported today results of its pivotal Phase III trauma trial with PolyHeme(R), its human hemoglobin-based oxygen-carrying red blood cell substitute. The trial was designed to seek an indication for use in the treatment of life-threatening red blood cell loss when transfusion is required and red blood cells are not available, not for use interchangeably with blood. This indication addresses a critical, unmet medical need.

The primary efficacy endpoint of the study was a dual superiority-noninferiority assessment of mortality at 30 days after injury. The margin to assess noninferiority, using the upper limit of the confidence interval, was set at 7% more than control. In the primary Modified Intent to Treat population, the upper limit was 7.65%. In the As Treated population, the upper limit was 7.06%. In the Per Protocol population, the upper limit was 6.29%.

Day 30 mortality was also a primary safety endpoint. Further analysis of the mortality data indicates that the difference in mortality at 30 days between patients who received PolyHeme beginning at the scene and continuing for up to 12 hours following injury, and control patients who received the standard of care, including early blood, was not statistically significant.

"The results of this study are best understood in the context of bleeding patients who do not have early access to blood transfusion," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "47 million Americans live more than an hour away from a trauma center where blood is available. Mortality rates in that scenario would be considerably higher than those observed in the control patients in the urban setting of this trial, where transit times were relatively short. We believe that when our data are extrapolated to patients who need an oxygen carrier and have delayed access
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:3/27/2015)... 2015 /CNW Telbec/ - Russell Williams , President ... (Rx&D), welcomes the 2015-2016 Quebec Budget, noting the fiscal ... the biopharmaceutical industry. However, the association is concerned about ... commend the government,s intent to strive for a balanced ... promote Quebec,s economic development is ...
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in ... on top as the country,s manufacturing leader in innovation ... ndp│analytics. According to the  analysis , the industry had ... last decade, accounting for 27 percent of average annual ... Short Video on Medicare Part D - Medicare ...
(Date:3/27/2015)... , March 27, 2015 The Temple Health ... April to a 5,000-square-foot building at 1802 South First St. ... area designated by the City of Temple ... & White and the Central Texas Veterans Health Care System, ... laboratory space to early stage biotechnology and life science companies. ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... teleconference to release report with ITPC. Kim says,foundations laid ... had to,build comprehensive health systems in the poorest settings.", ... ,The International Treatment Preparedness Coalition (ITPC), a group of ... its fifth,report on scale up of AIDS services: Missing ...
... BUFFALO, N.Y., Nov. 27 Kinex Pharmaceuticals LLC,announced ... Phase 1 human,testing. The study is entitled "A ... 1 study to evaluate safety, tolerability,and pharmacokinetics of ... to conventional therapies". The drug belongs to an ...
Cached Medicine Technology:New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 2New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 3New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target 4First Patient Dosed with KX2-391 in Phase 1 Clinical Trial 2
(Date:3/27/2015)... Tampa, FL (PRWEB) March 27, 2015 Florida ... Bay Storm as the team’s exclusive health care provider for ... care provider, Florida Hospital provides medical care and an athletic ... Bay Storm will kick off its season against the Cleveland ... , “This partnership is extremely important to us as ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 First Choice ... today. The new facility is located 12665 W Lake Houston ... a resident of Summerwood, I look forward to delivering the ... Dr. Sowell, Facility Medical Director of First Choice Emergency Room ... Emergency Room made a donation to Summer Creek High School ...
(Date:3/27/2015)... March 27, 2015 Top medical tourism ... patients travel to the Dominican Republic to benefit from ... clinic is turning the medical tourism industry upside-down and ... — with trustworthy services becoming the central influence. ... plastic surgeon. Patients are not only attracted to low-cost ...
(Date:3/27/2015)... California (PRWEB) March 27, 2015 ... Entertainment’s EcoLuxe Lounge in the Stardust Penthouse on ... Debbie Durkin, Los Angeles’ leading sustainable product TV ... behind this unforgettable day-long event, which featured some ... and ecologically sound products and services. , “We ...
(Date:3/27/2015)... Dallas, TX (PRWEB) March 27, 2015 ... Landscape – Germany” is an essential source of ... and reimbursement landscape in Germany. Germany’s increasingly elderly ... drivers of its pharmaceutical market. In 2013, the ... expected to increase at Compound Annual Growth Rate ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 2Health News:Dominican Republic Plastic Surgery Provider Turning Medical Tourism Upside-Down 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4
... 27 Inverness Medical Innovations, Inc. (NYSE: IMA ... of their health at home through the merger of rapid ... the quarter ended March 31, 2009.In the first quarter of ... to net revenue of $372.2 million in the first quarter ...
... Medimetriks Pharmaceuticals announced today that the ... (20% Urea) Foam to its core Dermatology and ... Approval in December 2002 and is patented through ... Medimetriks, plan to commercialize patent-protected therapies that offer ...
... Centers to Encourage Preventive Care , ... Mountain View, CA and San ... industry leader in personal genetics, and Palomar Pomerado Health (PPH), ... be offering the 23andMe Personal Genome Service for sale to San Diegans ...
... PLC Systems Inc. (OTC Bulletin Board: PLCSF) announced today that ... results for the first quarter ended March 31, 2009 before ... plans to host a conference call to discuss those results ... may be joined via telephone by dialing (866) 825-1708 or ...
... Economics Research Institute (HERI) is actively pursuing research ... U.S. health care delivery system through market-based solutions. ... ways to organize and finance the system in ... HERI,s chair, said, "We are interested in identifying ...
... urges health professionals to help reduce consumer confusionWASHINGTON, April ... June issue of the Journal of Nutrition ... stop demonizing high fructose corn syrup as the culprit ... fructose corn syrup,s impact on the American diet. "The ...
Cached Medicine News:Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 2Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 3Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 4Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 5Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 6Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 7Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 8Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 9Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 10Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 11Health News:Inverness Medical Innovations Announces First Quarter 2009 Results 12Health News:Medimetriks Pharmaceuticals Launches Two New Prescription Brands 2Health News:Medimetriks Pharmaceuticals Launches Two New Prescription Brands 3Health News:23andMe and Palomar Pomerado Health Partner to Give PPH Members Access to Their Genetic Information 2Health News:23andMe and Palomar Pomerado Health Partner to Give PPH Members Access to Their Genetic Information 3Health News:23andMe and Palomar Pomerado Health Partner to Give PPH Members Access to Their Genetic Information 4Health News:Health Economics Research Institute Call for Proposals--Improving Healthcare Through Market Solutions 2Health News:Experts Lay to Rest Long-Held Misconceptions About High Fructose Corn Syrup at ILSI-USDA Workshop 2Health News:Experts Lay to Rest Long-Held Misconceptions About High Fructose Corn Syrup at ILSI-USDA Workshop 3
... developer of laser diagnostics for ophthalmic applications, ... Tomograph 3 (HRT3), a newly-enhanced version of ... and management of glaucoma. ,Like its predecessor, ... a topographical image of a patients optic ...
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D...
... Fr Sur-Catch NT stone retrieval basket raises proven ... Its unique paired wire design and multi-sizing basket ... needs of each patient and procedure. Its ... use with the DURTM-8 Elite Ureteroscope and its ...
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
Medicine Products: